On Monday, PPMD’s Founding President Pat Furlong, CEO Dr. John Porter, and SVP of Legislation & Public Policy Annie Kennedy joined Duchenne stakeholders from around the world in a special one-day meeting to discuss robotic technology and the potential it holds for our community. PPMD – together with UPPMD – gathered the best and brightest robotics experts and engineers who are working to apply their innovations to Duchenne. We discussed the variety of technologies currently in…Continue
Parent Project Muscular Dystrophy (PPMD) has awarded University of Washington a $148,000 grant to continue the functional analysis of spectrin-like repeats in dystrophin. Led by Stanley C. Froehner, PhD, Sackler professor and chair of the Department of Physiology & Biophysics at University of Washington, this grant will provide funding so that more research can be completed before the team submits to the National Institutes of Health (NIH) for additional…Continue
Added by PPMD on April 20, 2015 at 11:00am — No Comments
BioMarin has provided the following update on redosing of drisapersen for a new clinical trial. Ambulation will not be an inclusion or exclusion criterion for enrollment, but boys will need to have been previously dosed as part of a clinical trial.
BioMarin Update on Duchenne Muscular Dystrophy…
Added by Ryan Fischer on April 14, 2015 at 9:00am — No Comments
Earlier this month Sarepta announced a change in leadership, with CMO Ed Kaye taking over as interim CEO.
Following that announcement the team at Sarepta organized a call with Duchenne patient organizations and foundations to update them…
Added by Ryan Fischer on April 13, 2015 at 11:00am — No Comments